|
US7244577B2
(en)
*
|
1997-04-15 |
2007-07-17 |
Merck & Co., Inc. |
Method of screening for modulator of LRP5 activity
|
|
US6780609B1
(en)
|
1998-10-23 |
2004-08-24 |
Genome Therapeutics Corporation |
High bone mass gene of 1.1q13.3
|
|
US6770461B1
(en)
|
1998-10-23 |
2004-08-03 |
Genome Therapeutics Corporation |
High bone mass gene of 11q13.3
|
|
US6699466B1
(en)
*
|
1999-08-05 |
2004-03-02 |
Research Corporation Technologies, Inc. |
IL-16 antagonist peptides and DNA encoding the peptides
|
|
FR2798138B1
(fr)
*
|
1999-09-03 |
2004-05-21 |
Centre Nat Rech Scient |
Clonage, expression et caracterisation du gene spg4 responsable de la forme la plus frequente de paraplegie spastique autosomique dominante
|
|
CN1454256A
(zh)
*
|
2000-04-05 |
2003-11-05 |
基因组治疗公司 |
11q13.3的高骨量基因
|
|
EP1285002B1
(en)
*
|
2000-05-26 |
2007-07-18 |
Oscient Pharmaceuticals Corporation |
Regulating lipid levels via the zmax1 or hbm gene
|
|
US7186515B1
(en)
|
2000-06-02 |
2007-03-06 |
University Of Connecticut Health Center |
Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
AU6669401A
(en)
|
2000-06-02 |
2001-12-11 |
Univ Connecticut Health Ct |
Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
|
|
US7179462B2
(en)
|
2000-06-02 |
2007-02-20 |
University Of Connecticut Health Center |
α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
EP1313753A4
(en)
*
|
2000-08-18 |
2004-09-15 |
Proskelia |
REGULATORY GENE AND SYSTEM FOR USE IN THE DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS
|
|
WO2002074906A2
(en)
*
|
2001-03-16 |
2002-09-26 |
Eli Lilly And Company |
Lp mammalian proteins; related reagents
|
|
US7416849B2
(en)
*
|
2001-05-11 |
2008-08-26 |
Oscient Pharmaceuticals Corporation |
HBM variants that modulate bone mass and lipid levels
|
|
US20040221326A1
(en)
*
|
2001-05-11 |
2004-11-04 |
Philip Babij |
Transgenic animal model of bone mass modulation
|
|
US7514594B2
(en)
|
2001-05-11 |
2009-04-07 |
Wyeth |
Transgenic animal model of bone mass modulation
|
|
EP1395285A4
(en)
*
|
2001-05-17 |
2005-06-01 |
Genome Therapeutics Corp |
REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS
|
|
US20040038860A1
(en)
|
2002-05-17 |
2004-02-26 |
Allen Kristina M. |
Reagents and methods for modulating dkk-mediated interactions
|
|
PL375043A1
(en)
|
2001-08-20 |
2005-11-14 |
University Of Connecticut Health Center |
Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin, useful for the treatment of cancer and infectious disease
|
|
GB2381790A
(en)
*
|
2001-09-26 |
2003-05-14 |
Glaxo Group Ltd |
LDL-receptor polypeptides
|
|
JP2005220022A
(ja)
*
|
2002-03-08 |
2005-08-18 |
Anges Mg Inc |
Ｗｎｔの新規作用、及び、疾患治療への応用
|
|
US7169559B2
(en)
*
|
2002-05-13 |
2007-01-30 |
Fonterra Corporate Research and Development Ltd. |
LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
|
|
US20030219793A1
(en)
*
|
2002-10-04 |
2003-11-27 |
Carulli John P. |
High bone mass gene of 11q13.3
|
|
WO2005049640A2
(en)
|
2003-11-17 |
2005-06-02 |
Merck & Co., Inc. |
Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
|
|
US7473770B2
(en)
|
2003-11-17 |
2009-01-06 |
Merck & Co., Inc. |
Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof
|
|
EP1692167A2
(en)
*
|
2003-11-24 |
2006-08-23 |
Gunnar Westin |
Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment
|
|
CA2798432A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
|
EA201291181A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
|
KR20140091031A
(ko)
|
2011-11-04 |
2014-07-18 |
노파르티스 아게 |
저밀도 지단백질-관련 단백질 6 (lrp6) - 반감기 연장제 구축물
|
|
TWI887192B
(zh)
|
2017-05-31 |
2025-06-21 |
比利時商艾伯林克斯公司 |
拮抗腫瘤細胞中wnt訊息傳導之多肽
|